Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction

Current Pharmaceutical Design

Volumn 16, Issue 14, 2010, Pages 1619-1633

  Gur, Serap ^a   Kadowitz, Philip J ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Activators; Erectile function; Nitric oxide; PDE5; Soluble guanylate cyclase; Stimulators; Treatment

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; A 778935; BAY 632521; CFM 1571; CYCLIC GMP; GUANYLATE CYCLASE ACTIVATOR; HEME; HMR 1766; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; S 3448; UNCLASSIFIED DRUG; ENZYME ACTIVATOR; GUANYLATE CYCLASE;

AGING; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG STRUCTURE; ERECTILE DYSFUNCTION; HUMAN; MALE; MOUSE; NERVE INJURY; NITRERGIC NERVE; NONHUMAN; PATHOPHYSIOLOGY; PENIS ERECTION; PEYRONIE DISEASE; PRIAPISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; METABOLISM; REVIEW; SOLUBILITY;

ENZYME ACTIVATORS; ERECTILE DYSFUNCTION; GUANYLATE CYCLASE; HUMANS; MALE; NITRIC OXIDE; SOLUBILITY;

EID: 77955370744     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791164162     Document Type: Article

References (164)

1. Schmidt HH, Walter U. NO at work. Cell 1994; 78(6): 919-25.
2. Stone JR, Marletta MA. The ferrous heme of soluble guanylate cyclase: formation of hexacoordinate complexes with carbon monoxide and nitrosomethane. Biochemistry 1995; 34(50): 16397-403.
3. Zabel U, Hausler C, Weeger M, Schmidt HH. Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione s-transferase affinity tag. J Biol Chem 1999; 274(26): 18149-52.
4. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 2006; 86(1): 1-23.
5. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75(4): 725-48.
6. Stone JR, Marletta MA. Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry 1994; 33(18): 5636-40.
7. Humbert P, Niroomand F, Fischer G, Mayer B, Koesling D, Hinsch KD, et al. Purification of soluble guanylyl cyclase from bovine lung by a new immunoaffinity chromatographic method. Eur J Biochem 1990; 190(2): 273-8.
8. Mohanakumar KP, Thomas B, Sharma SM, Muralikrishnan D, Chowdhury R, Chiueh CC. Nitric oxide: an antioxidant and neuroprotector. Ann NY Acad Sci 2002; 962: 389-401.
9. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H SA, Meurer S, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006; 116(9): 2552-61.
10. Dierks EA, Burstyn JN. Nitric oxide (NO), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase. Biochem Pharmacol 1996; 51(12): 1593-600.
11. Schmidt P, Schramm M, Schroder H, Stasch JP. Preparation of heme-free soluble guanylate cyclase. Protein Expr Purif 2003; 31(1): 42-6.
12. Gerzer R, Bohme E, Hofmann F, Schultz G. Soluble guanylate cyclase purified from bovine lung contains heme and copper. FEBS Lett 1981; 132(1): 71-4.
13. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5(9): 755-68.
14. Mayer B, Koesling D. cGMP signalling beyond nitric oxide. Trends Pharmacol Sci 2001; 22(11): 546-8.
15. Zabel U, Weeger M, La M, Schmidt HH. Human soluble guanylate cyclase: functional expression and revised isoenzyme family. Biochem J 1998; 335 (Pt 1): 51-7.
16. Iyer LM, Anantharaman V, Aravind L. Ancient conserved domains shared by animal soluble guanylyl cyclases and bacterial signaling proteins. BMC Genomics 2003; 4(1): 5.
17. Nioche P, Berka V, Vipond J, Minton N, Tsai AL, Raman CS. Femtomolar sensitivity of a NO sensor from Clostridium botulinum. Science 2004; 306(5701): 1550-3.
18. Pellicena P, Karow DS, Boon EM, Marletta MA, Kuriyan J. Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases. Proc Natl Acad Sci USA 2004; 101(35): 12854-9.
19. Schmidt PM, Schramm M, Schroder H, Wunder F, Stasch JP. Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem 2004; 279(4): 3025-32.
20. Ignarro LJ, Adams JB, Horwitz PM, Wood KS. Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms. J Biol Chem 1986; 261(11): 4997-5002.
21. Foerster J, Harteneck C, Malkewitz J, Schultz G, Koesling D. A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits. Eur J Biochem 1996; 240(2): 380-6.
22. Feelisch M, Kotsonis P, Siebe J, Clement B, Schmidt HH. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol Pharmacol 1999; 56(2): 243-53.
23. Hwang TL, Wu CC, Teng CM. Comparison of two soluble guanylyl cyclase inhibitors, methylene blue and ODQ, on sodium nitroprusside-induced relaxation in guinea-pig trachea. Br J Pharmacol 1998; 125(6): 1158-63.
24. Kannan MS, Johnson DE. Modulation of nitric oxide-dependent relaxation of pig tracheal smooth muscle by inhibitors of guanylyl cyclase and calcium activated potassium channels. Life Sci 1995; 56(25): 2229-38.
25. Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT, Marletta MA. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 2000; 39(35): 10848-54.
26. Ignarro LJ, Wood KS, Wolin MS. Activation of purified soluble guanylate cyclase by protoporphyrin IX. Proc Natl Acad Sci USA 1982; 79(9): 2870-3.
27. Koglin M, Behrends S. A functional domain of the alpha1 subunit of soluble guanylyl cyclase is necessary for activation of the enzyme by nitric oxide and YC-1 but is not involved in heme binding. J Biol Chem 2003; 278(14): 12590-7.
28. Zhao Y, Hoganson C, Babcock GT, Marletta MA. Structural changes in the heme proximal pocket induced by nitric oxide binding to soluble guanylate cyclase. Biochemistry 1998; 37(36): 12458-64.
29. Wolin MS. Reactive oxygen species and the control of vascular function. Am J Physiol Heart Circ Physiol 2009; 296(3): H539-49.
30. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol 1998; 358(1): 113-22.
31. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, et al. Pharmacological actions of a novel NOindependent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 2002; 135(2): 333-43.
32. Schmidt P, Schramm M, Schroder H, Stasch JP. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol 2003; 468(3): 167-74.
33. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994; 84(12): 4226-33.
34. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001; 410(6825): 212-5.
35. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, et al. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002; 136(5): 773-83.
36. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz J, Ducke B, Feurer A, et al. NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 2001; 11(6): 781-4.
37. Stone JR, Marletta MA. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chem Biol 1998; 5(5): 255-61.
38. Friebe A, Schultz G, Koesling D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J 1996; 15(24): 6863-8.
39. Mulsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimu lator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 1997; 120(4): 681-9.
40. Wedel B, Humbert P, Harteneck C, Foerster J, Malkewitz J, Bohme E, et al. Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc Natl Acad Sci USA 1994; 91(7): 2592-6.
41. Russwurm M, Mergia E, Mullershausen F, Koesling D. Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J Biol Chem 2002; 277(28): 24883-8.
42. Cary SP, Winger JA, Marletta MA. Tonic and acute nitric oxide signaling through soluble guanylate cyclase is mediated by nonheme nitric oxide, ATP, and GTP. Proc Natl Acad Sci USA 2005; 102(37): 13064-9.
43. Russwurm M, Koesling D. NO activation of guanylyl cyclase. EMBO J 2004; 23(22): 4443-50.
44. Hoenicka M, Becker EM, Apeler H, Sirichoke T, Schroder H, Gerzer R, et al. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J Mol Med 1999; 77(1): 14-23.
45. Denninger JW, Schelvis JP, Brandish PE, Zhao Y, Babcock GT, Marletta MA. Interaction of soluble guanylate cyclase with YC-1: kinetic and resonance Raman studies. Biochemistry 2000; 39(14): 4191-8.
46. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 1999; 127(1): 195-203.
47. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009; (191): 277-308.
48. Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC. YC-1, a nitric oxideindependent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 1997; 320(2-3): 161-6.
49. Nakane M. Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application. Clin Chem Lab Med 2003; 41(7): 865-70.
50. Linder AE, McCluskey LP, Cole KR, 3rd, Lanning KM, Webb RC. Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. J Pharmacol Exp Ther 2005; 314(1): 9-15.
51. Liu YN, Pan SL, Peng CY, Guh JH, Huang DM, Chang YL, et al. YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J Pharmacol Exp Ther 2006; 316(1): 35-41.
52. Tulis DA, Durante W, Peyton KJ, Chapman GB, Evans AJ, Schafer AI. YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem Biophys Res Commun 2000; 279(2): 646-52.
53. Shin DH, Kim JH, Jung YJ, Kim KE, Jeong JM, Chun YS, et al. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 2007; 255(1): 107-16.
54. Boulet I, Ralph S, Stanley E, Lock P, Dunn AR, Green SP, et al. Lipopolysaccharide- and interferon-gamma-induced expression of hck and lyn tyrosine kinases in murine bone marrow-derived macrophages. Oncogene 1992; 7(4): 703-10.
55. Lu DY, Tang CH, Liou HC, Teng CM, Jeng KC, Kuo SC, et al. YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-kappaB in microglia. Br J Pharmacol 2007; 151(3): 396-405.
56. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, et al. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004; 110(15): 2253-9.
57. Priviero FB, Zemse SM, Teixeira CE, Webb RC. Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats. Am J Hypertens 2009; 22(5): 493-9.
58. Iwatani Y, Kosugi K, Isobe-Oku S, Atagi S, Kitamura Y, Kawasaki H. Endothelium removal augments endothelium-independent vasodilatation in rat mesenteric vascular bed. Br J Pharmacol 2008; 154(1): 32-40.
59. Mullershausen F, Russwurm M, Friebe A, Koesling D. Inhibition of phosphodiesterase type 5 by the activator of nitric oxidesensitive guanylyl cyclase BAY 41-2272. Circulation 2004; 109(14): 1711-3.
60. Tsuruda T, Hatakeyama K, Masuyama H, Sekita Y, Imamura T, Asada Y, et al. Pharmacological stimulation of soluble guanylate cyclase modulates hypoxia-inducible factor-1alpha in rat heart. Am J Physiol Heart Circ Physiol 2009; 297(4): H1274-80.
61. Mujoo K, Sharin VG, Bryan NS, Krumenacker JS, Sloan C, Parveen S, et al. Role of nitric oxide signaling components in differentiation of embryonic stem cells into myocardial cells. Proc Natl Acad Sci USA 2008; 105(48): 18924-9.
62. Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA. Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. J Pharmacol Exp Ther 2008; 326(2): 380-7.
63. Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 2002; 135(2): 344-55.
64. Selwood DL, Brummell DG, Budworth J, Burtin GE, Campbell RO, Chana SS, et al. Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J Med Chem 2001; 44(1): 78-93.
65. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bolkow D, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33(4): 785-92.
66. Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Muller D, Schluter KD, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32(4): 881-91.
67. Frey R, Muck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008; 48(8): 926-34.
68. Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009; 4(5): 853-65.
69. Nakane M, Kolasa T, Chang R, Miller LN, Moreland RB, Brioni JD. Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator. J Pharmacol Sci 2006; 102(2): 231-8.
70. Miller LN, Nakane M, Hsieh GC, Chang R, Kolasa T, Moreland RB, et al. A-350619: a novel activator of soluble guanylyl cyclase. Life Sci 2003; 72(9): 1015-25.
71. Schindler U, Strobel H, Schonafinger K, Linz W, Lohn M, Martorana PA, et al. Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol 2006; 69(4): 1260-8.
72. Frey R, Muck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol 2008; 48(12): 1400-10.
73. Rothkegel C, Schmidt PM, Stoll F, Schroder H, Schmidt HH, Stasch JP. Identification of residues crucially involved in soluble guanylate cyclase activation. FEBS Lett 2006; 580(17): 4205-13.
74. Hobbs AJ. Soluble guanylate cyclase: an old therapeutic target revisited. Br J Pharmacol 2002; 136(5): 637-40.
75. Forrest A, Molleman A, Parsons M. The responses to manipulation of extracellular and intracellular calcium are altered in the streptozotocin-diabetic rat colon and ileum. Eur J Pharmacol 2005; 509(1): 77-83.
76. Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus T, et al. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res 2009; 105(1): 33-41.
77. Zhou Z, Pyriochou A, Kotanidou A, Dalkas G, van Eickels M, Spyroulias G, et al. Soluble guanylyl cyclase activation by HMR 1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol 2008; 295(4): H1763-71.
78. Schafer A, Flierl U, Kobsar A, Eigenthaler M, Ertl G, Bauersachs J. Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats. Arterioscler Thromb Vasc Biol 2006; 26(12): 2813-8.
79. Kasseckert SA, Schafer C, Kluger A, Gligorievski D, Tillmann J, Schluter KD, et al. Stimulation of cGMP signalling protects coronary endothelium against reperfusion-induced intercellular gap formation. Cardiovasc Res 2009; 83(2): 381-7.
80. Schmidt HH, Schmidt PM, Stasch JP. NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 2009; (191): 309-39.
81. Cellek S, Rees RW, Kalsi J. A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction. Expert Opin Investig Drugs 2002; 11(11): 1563-73.
82. Feil R, Kemp-Harper B. cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep 2006; 7(2): 149-53.
83. Kemp-Harper B, Feil R. Meeting report: cGMP matters. Sci Signal 2008; 1(9): pe12.
84. Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 2009; 119(21): 2781-8.
85. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001; 53(3): 417-50.
86. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75(1): 191-236.
87. Ignarro LJ. Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling. Pharmacol Toxicol 1990; 67(1): 1-7.
88. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326(2): 90-4.
89. Linder AE, Leite R, Lauria K, Mills TM, Webb RC. Penile erection requires association of soluble guanylyl cyclase with endothelial caveolin-1 in rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol 2006; 290(5): R1302-8.
90. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151(1): 54-61.
91. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMPspecific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8(2): 47-52.
92. Foresta C, Caretta N, Garolla A, Rossato M. Erectile function in elderly: role of androgens. J Endocrinol Invest 2003; 26(3 Suppl): 77-81.
93. Gurbuz N, Mammadov E, Usta MF. Hypogonadism and erectile dysfunction: an overview. Asian J Androl 2008; 10(1): 36-43.
94. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl 2003; 24(6 Suppl): S17-37.
95. Cartledge JJ, Eardley I, Morrison JF. Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. BJU Int 2001; 87(4): 394-401.
96. Musicki B, Kramer MF, Becker RE, Burnett AL. Age-related changes in phosphorylation of endothelial nitric oxide synthase in the rat penis. J Sex Med 2005; 2(3): 347-55; discussion 55-7.
97. Ferrini MG, Davila HH, Valente EG, Gonzalez-Cadavid NF, Rajfer J. Aging-related induction of inducible nitric oxide synthase is vasculo-protective to the arterial media. Cardiovasc Res 2004; 61(4): 796-805.
98. Yousif MH, Kehinde EO, Benter IF. Different responses to angiotensin-(1-7) in young, aged and diabetic rabbit corpus cavernosum. Pharmacol Res 2007; 56(3): 209-16.
99. Pu XY, Wang XH, Gao WC, Yang ZH, Li SL, Wang HP, et al. Insulin-like growth factor-1 restores erectile function in aged rats: modulation the integrity of smooth muscle and nitric oxide-cyclic guanosine monophosphate signaling activity. J Sex Med 2008; 5(6): 1345-54.
100. Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Davila HH, Rajfer J, et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod 2007; 76(5): 915-23.
101. Caretta N, Ferlin A, Palego PF, Foresta C. Erectile dysfunction in aging men: testosterone role in therapeutic protocols. J Endocrinol Invest 2005; 28(11 Suppl Proceedings): 108-11.
102. Morelli A, Vignozzi L, Filippi S, Mancina R, Maggi M. Erectile dysfunction: molecular biology, pathophysiology and pharmacological treatment. Minerva Urol Nefrol 2005; 57(2): 85-90.
103. Rosen RC. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opin Urol 2006; 16(1): 11-9.
104. McVary KT. Interrelation of erectile dysfunction and lower urinary tract symptoms. Drugs Today (Barc) 2005; 41(8): 527-36.
105. Gur S, Kadowitz PJ, Hellstrom WJ. Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction: implications for sexual dysfunction. Drugs 2008; 68(2): 209-29.
106. Mateos-Caceres PJ, Garcia-Cardoso J, Lapuente L, Zamorano-Leon JJ, Sacristan D, de Prada TP, et al. Soluble guanylate cyclase beta1-subunit expression is increased in mononuclear cells from patients with erectile dysfunction. Int J Impot Res 2006; 18(5): 432-7.
107. Abdel Aziz MT, Mostafa T, Atta H, Mahfouz S, Wassef M, Fouad H, et al. Effect of HO-1 cDNA-liposome complex transfer on erectile signalling of aged rats. Andrologia 2009; 41(3): 176-83.
108. Hosogai N, Takakura S, Manda T, Mutoh S. Enzyme activities of the nitric oxide-cGMP pathway in corpus cavernosum isolated from middle-aged rats. Eur J Pharmacol 2003; 473(1): 65-70.
109. Cai C, Chen SY, Zheng Z, Omwancha J, Lin MF, Balk SP, et al. Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation. Oncogene 2007; 26(11): 1606-15.
110. Gonzalez-Cadavid NF, Rajfer J. Molecular pathophysiology and gene therapy of aging-related erectile dysfunction. Exp Gerontol 2004; 39(11-12): 1705-12.
111. Ushiyama M, Morita T, Kuramochi T, Yagi S, Katayama S. Erectile dysfunction in hypertensive rats results from impairment of the relaxation evoked by neurogenic carbon monoxide and nitric oxide. Hypertens Res 2004; 27(4): 253-61.
112. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, et al. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci USA 2004; 101(47): 16671-6.
113. Miner M, Billups KL. Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins. J Sex Med 2008; 5(5): 1066-78.
114. Heruti R, Arbel Y, Steinvil A, Zarka S, Saar N, Kinori M, et al. Pure hypertriglyceridemia might be associated with erectile dysfunction: a pilot study. J Sex Med 2008; 5(5): 1230-6.
115. Xie D, Odronic SI, Wu F, Pippen AM, Donatucci CF, Annex BH. A mouse model of hypercholesterolemia-induced erectile dysfunction. J Sex Med 2007; 4(4 Pt 1): 898-907.
116. Kojda G, Kottenberg K, Hacker A, Noack E. Alterations of the vascular and the myocardial guanylate cyclase/cGMP-system induced by long-term hypertension in rats. Pharm Acta Helv 1998; 73(1): 27-35.
117. Kloss S, Bouloumie A, Mulsch A. Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. Hypertension 2000; 35(1 Pt 1): 43-7.
118. Morawietz H, Weber M, Rueckschloss U, Lauer N, Hacker A, Kojda G. Upregulation of vascular NAD(P)H oxidase subunit gp91phox and impairment of the nitric oxide signal transduction pathway in hypertension. Biochem Biophys Res Commun 2001; 285(5): 1130-5.
119. Shamloul R, Wang R. Increased intracavernosal pressure response in hypertensive rats after chronic hemin treatment. J Sex Med 2006; 3(4): 619-27.
120. Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 2006; 8(6): 675-84.
121. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5(8): 689-702.
122. Ahn G, Chung H, Lee C, Kang K, Ahn B. Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis. Asian J Androl 2009; 11(4): 435-42.
123. Chang S, Hypolite JA, Velez M, Changolkar A, Wein AJ, Chacko S, et al. Downregulation of cGMP-dependent protein kinase-1 activity in the corpus cavernosum smooth muscle of diabetic rabbits. Am J Physiol Regul Integr Comp Physiol 2004; 287(4): R950-60.
124. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2004; 101(24): 9121-6.
125. Teixeira CE, Jin L, Ying Z, Palmer T, Priviero FB, Webb RC. Expression and functional role of the RhoA/Rho-kinase pathway in rat coeliac artery. Clin Exp Pharmacol Physiol 2005; 32(10): 817-24.
126. Chitaley K, Webb RC. Nitric oxide induces dilation of rat aorta via inhibition of rho-kinase signaling. Hypertension 2002; 39(2 Pt 2): 438-42.
127. Yildirim S, Ayan S, Sarioglu Y, Gultekin Y, Uma S. Does diabetes mellitus affect the progress of tolerance to isosorbide dinitrate (ISDN) in corporal tissue? Nitric Oxide 2000; 4(1): 29-34.
128. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990; 170(2): 843-50.
129. Kalsi JS, Rees RW, Hobbs AJ, Royle M, Kell PD, Ralph DJ, et al. BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J Urol 2003; 169(2): 761-6.
130. Angulo J, Peiro C, Cuevas P, Gabancho S, Fernandez A, Gonzalez-Corrochano R, et al. The novel antioxidant, AC3056 (2,6-di-tbutyl-4-((dimethyl-4-methoxyphenylsilyl)methyloxy)phenol), reverses erectile dysfunction in diabetic rats and improves NOmediated responses in penile tissue from diabetic men. J Sex Med 2009; 6(2): 373-87.
131. Wang R. Penile rehabilitation after radical prostatectomy: where do we stand and where are we going? J Sex Med 2007; 4(4 Pt 2): 1085-97.
132. Nangle MR, Keast JR. Reduced efficacy of nitrergic neurotransmission exacerbates erectile dysfunction after penile nerve injury despite axonal regeneration. Exp Neurol 2007; 207(1): 30-41.
133. McCullough AR. Rehabilitation of erectile function following radical prostatectomy. Asian J Androl 2008; 10(1): 61-74.
134. Bella AJ, Lin G, Lin CS, Hickling DR, Morash C, Lue TF. Nerve growth factor modulation of the cavernous nerve response to injury. J Sex Med 2009; 6 (Suppl 3): 347-52.
135. Fandel TM, Bella AJ, Lin G, Tantiwongse K, Lin CS, Pohl J, et al. Intracavernous growth differentiation factor-5 therapy enhances the recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med 2008; 5(8): 1866-75.
136. Lysiak JJ, Yang SK, Klausner AP, Son H, Tuttle JB, Steers WD. Tadalafil increases Akt and extracellular signal-regulated kinase 1/2 activation, and prevents apoptotic cell death in the penis following denervation. J Urol 2008; 179(2): 779-85.
137. Stern M, Bicker G. Nitric oxide regulates axonal regeneration in an insect embryonic CNS. Dev Neurobiol 2008; 68(3): 295-308.
138. Evgenov OV, Kohane DS, Bloch KD, Stasch JP, Volpato GP, Bellas E, et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007; 176(11): 1138-45.
139. Knorr A, Hirth-Dietrich C, Alonso-Alija C, Harter M, Hahn M, Keim Y, et al. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 2008; 58(2): 71-80.
140. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 2007; 572(1): 12-22.
141. Masuyama H, Tsuruda T, Kato J, Imamura T, Asada Y, Stasch JP, et al. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 2006; 48(5): 972-8.
142. Wang Y, Kramer S, Loof T, Martini S, Kron S, Kawachi H, et al. Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am J Physiol Renal Physiol 2006; 290(1): F167-76.
143. Mi T, Abbasi S, Zhang H, Uray K, Chunn JL, Xia LW, et al. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 2008; 118(4): 1491-501.
144. Claudino MA, Franco-Penteado CF, Corat MA, Gimenes AP, Passos LA, Antunes E, et al. Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the NOcGMP signaling pathway. J Sex Med 2009; 6(8): 2187-96.
145. Hsieh GC, O'Neill AB, Moreland RB, Sullivan JP, Brioni JD. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur J Pharmacol 2003; 458(1-2): 183-9.
146. Mizusawa H, Hedlund P, Brioni JD, Sullivan JP, Andersson KE. Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J Urol 2002; 167(5): 2276-81.
147. Nakane M, Hsieh G, Miller LN, Chang R, Terranova MA, Moreland RB, et al. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int J Impot Res 2002; 14(2): 121-7.
148. Brioni JD, Nakane M, Hsieh GC, Moreland RB, Kolasa T, Sullivan JP. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res 2002; 14(1): 8-14.
149. Hallen K, Gustafsson LE, Wiklund NP. Nerve-induced release of nitric oxide from the rabbit corpus cavernosum is modulated by cyclic guanosine 3',5'-monophosphate. Neuroscience 2005; 133(1): 169-74.
150. Baracat JS, Teixeira CE, Okuyama CE, Priviero FB, Faro R, Antunes E, et al. Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum. Eur J Pharmacol 2003; 477(2): 163-9.
151. Bischoff E, Stasch JP. Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition. Circulation 2004; 110(12): e320-1; author reply e-1.
152. Bischoff E, Schramm M, Straub A, Feurer A, Stasch JP. BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxidedependent penile erection in vivo. Urology 2003; 61(2): 464-7.
153. Claudino MA, Franco-Penteado CF, Corat MA, Gimenes AP, Passos LA, Antunes E, et al. Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the NOcGMP signaling pathway. J Sex Med 2009; 6(8): 2187-96.
154. Toque HA, Antunes E, Teixeira CE, De Nucci G. Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra. Urology 2008; 72(3): 711-5.
155. Nimmegeers S, Sips P, Buys E, Decaluwe K, Brouckaert P, Van de Voorde J. Role of the soluble guanylyl cyclase alpha1-subunit in mice corpus cavernosum smooth muscle relaxation. Int J Impot Res 2008; 20(3): 278-84.
156. Teixeira CE, Priviero FB, Webb RC. Effects of 5-cyclopropyl-2-[1- (2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrim idin-4- ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-type, neuronal, and endothelial nitric-oxide synthase null mice. J Pharmacol Exp Ther 2007; 322(3): 1093-102.
157. Claudino MA, Priviero FB, Camargo EA, Teixeira CE, De Nucci G, Antunes E, et al. Protective effect of prior physical conditioning on relaxing response of corpus cavernosum from rats made hypertensive by nitric oxide inhibition. Int J Impot Res 2007; 19(2): 189-95.
158. Teixeira CE, Priviero FB, Claudino MA, Baracat JS, De Nucci G, Webb RC, et al. Stimulation of soluble guanylyl cyclase by BAY 41-2272 relaxes anococcygeus muscle: interaction with nitric oxide. Eur J Pharmacol 2006; 530(1-2): 157-65.
159. Wespes E. Smooth muscle pathology and erectile dysfunction. Int J Impot Res 2002; 14 (Suppl 1): S17-21.
160. Lau DH, Kommu S, Mumtaz FH, Morgan RJ, Thompson CS, Mikhailidis DP. The management of phosphodiesterase-5 (PDE5) inhibitor failure. Curr Vasc Pharmacol 2006; 4(2): 89-93.
161. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148(3): 1019-29.
162. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006; 98(6): 1259-63.
163. Ryu JK, Shin HY, Song SU, Oh SM, Piao S, Han JY, et al. Downregulation of angiogenic factors and their downstream target molecules affects the deterioration of erectile function in a rat model of hypercholesterolemia. Urology 2006; 67(6): 1329-34.
164. Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2008.